TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
TRAVERE THERAPEUTICS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Read chart description and values below for full signed amounts, including zero items.Inducement expense → operating reconciliation: $40,008,000.00Accrued expenses → operating reconciliation: $30,094,000.00Share based compensation → operating reconciliation: $21,788,000.00Accounts receivable → operating reconciliation: $6,642,000.00Depreciation and amortization → operating reconciliation: $4,234,000.00Other current and non-current liabilities → operating reconciliation: $2,947,000.00Foreign currency remeasurement impact → operating reconciliation: $950,000.00operating reconciliation → Net cash from operating activities: $58,071,000.00operating reconciliation → Net loss from continuing operations: $34,797,000.00operating reconciliation → Accounts payable: $5,402,000.00operating reconciliation → Prepaid expenses and other current and non-current assets: $3,075,000.00operating reconciliation → Inventory: $2,708,000.00operating reconciliation → Other: $2,610,000.00Proceeds from issuance of 2032 convertible senior notes → financing reconciliation: $525,000,000.00Proceeds from exercise of stock options → financing reconciliation: $27,841,000.00Proceeds from issuances under the employee stock purchase plan → financing reconciliation: $2,356,000.00financing reconciliation → Net cash from financing activities: $187,517,000.00financing reconciliation → Repurchase of 2029 convertible senior notes including premium: $350,885,000.00financing reconciliation → Payment of debt issuance costs: $16,270,000.00financing reconciliation → Payment of guaranteed minimum royalty: $525,000.00Net cash used in investing activities → investing reconciliation: $206,287,000.00Proceeds from the sale and maturity of marketable debt securities → investing reconciliation: $36,367,000.00investing reconciliation → Purchase of marketable debt securities: $221,583,000.00investing reconciliation → Purchase of intangible assets: $21,071,000.00Exchange-rate effect → Cash sources and uses: $72,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $78,362,000.00Net cash from operating activities → Cash sources and uses: $58,071,000.00Net cash from financing activities → Cash sources and uses: $187,517,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $117,735,000.00Cash sources and uses → Net cash used in investing activities: $206,287,000.00Net loss from continuing operations: -$34,797,000.00Continuing ops income (loss)−$34.80 MDepreciation and amortization: $4,234,000.00Depreciation & amortization+$4.23 MShare based compensation: $21,788,000.00Stock-based compensation+$21.79 MForeign currency remeasurement impact: $950,000.00FX transaction gain & loss+$950.00 KInducement expense: $40,008,000.00Convertible debt inducement+$40.01 MOther: -$2,610,000.00Other non-cash items−$2.61 MAccounts receivable: $6,642,000.00Accounts receivable+$6.64 MInventory: -$2,708,000.00Inventories−$2.71 MPrepaid expenses and other current and non-current assets: -$3,075,000.00Prepaid & other assets−$3.08 MAccounts payable: -$5,402,000.00Payables & accrued liabilities−$5.40 MAccrued expenses: $30,094,000.00Accrued & other liabilities+$30.09 MDeferred revenue: $0.00Other current and non-current liabilities: $2,947,000.00Other operating liabilities+$2.95 MNet cash from operating activities: $58,071,000.00Operating cash+$58.07 Moperating reconciliation: $106,663,000.00Payment of guaranteed minimum royalty: -$525,000.00Minimum royalty paid−$525.00 KProceeds from issuance of 2032 convertible senior notes: $525,000,000.00Convertible debt issued+$525.00 MPayment of debt issuance costs: -$16,270,000.00Debt issuance costs−$16.27 MRepurchase of 2029 convertible senior notes including premium: -$350,885,000.00Convertible debt repaid−$350.89 MProceeds from exercise of stock options: $27,841,000.00Stock option exercises+$27.84 MProceeds from issuances under the employee stock purchase plan: $2,356,000.00Stock plan proceeds+$2.36 MNet cash from financing activities: $187,517,000.00Financing cash+$187.52 Mfinancing reconciliation: $555,197,000.00Proceeds from the sale and maturity of marketable debt securities: $36,367,000.00AFS securities proceeds+$36.37 MPurchase of marketable debt securities: -$221,583,000.00Marketable securities purchases−$221.58 MPurchase of intangible assets: -$21,071,000.00Intangible asset purchases−$21.07 MOther: $0.00Net cash used in investing activities: -$206,287,000.00. Cash required to fund net payments.Investing cash−$206.29 Minvesting reconciliation: $242,654,000.00Cash sources and uses: $324,022,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $78,362,000.00Beginning cash$78.36 MEnding cash: Cash, cash equivalents, and restricted cash: $117,735,000.00Ending cash$117.74 MExchange-rate effect: $72,000.00FX effect+$72.00 KCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsNet loss −$34.80M + net operating adjustments $92.87M = operating cash +$58.07MFree cash flowNot availableCash flow / Net incomeUnavailableOperating cash flow ÷ net incomeNet cash change+$39.37 MEnding cash − beginning cash
Chart details

TRAVERE THERAPEUTICS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
78,362,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
58,071,000 US dollars. Net cash provided.
Net loss from continuing operations
negative 34,797,000 US dollars
Depreciation and amortization
4,234,000 US dollars
Share based compensation
21,788,000 US dollars
Foreign currency remeasurement impact
950,000 US dollars
Inducement expense
40,008,000 US dollars
Other
negative 2,610,000 US dollars
Accounts receivable
6,642,000 US dollars
Inventory
negative 2,708,000 US dollars
Prepaid expenses and other current and non-current assets
negative 3,075,000 US dollars
Accounts payable
negative 5,402,000 US dollars
Accrued expenses
30,094,000 US dollars
Deferred revenue
0 US dollars
Other current and non-current liabilities
2,947,000 US dollars
Investing activities
negative 206,287,000 US dollars. Net cash used.
Proceeds from the sale and maturity of marketable debt securities
36,367,000 US dollars
Purchase of marketable debt securities
negative 221,583,000 US dollars
Purchase of intangible assets
negative 21,071,000 US dollars
Other
0 US dollars
Financing activities
187,517,000 US dollars. Net cash provided.
Payment of guaranteed minimum royalty
negative 525,000 US dollars
Proceeds from issuance of 2032 convertible senior notes
525,000,000 US dollars
Payment of debt issuance costs
negative 16,270,000 US dollars
Repurchase of 2029 convertible senior notes including premium
negative 350,885,000 US dollars
Proceeds from exercise of stock options
27,841,000 US dollars
Proceeds from issuances under the employee stock purchase plan
2,356,000 US dollars
Operating adjustment reconciliation
106,663,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
555,197,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
242,654,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
72,000 US dollars
Ending cash on Jun 30, 2026
117,735,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
324,022,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
39,373,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Unavailable. Operating cash flow and reconciliation net income for the same period are required.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$34.80M + net operating adjustments $92.87M = operating cash +$58.07M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!